Loading patent…
AssigneeRoche Diagnostics Operations, Inc.
InventorsMichael Gerg, Lars Hillringhaus, Ute Jucknischke, Anna Christine Muth, Tobias Oelschlaegel, Boris Pinchuk, Michael Schraeml, Joanna Siebenhaar, Laurence Thirault
Estimating the term…
The present invention relates to monoclonal antibodies and antigen binding fragments that specifically bind to α-1,6-core-fucosylated alpha-fetoprotein (AFP), which is the core component of AFP-L3. Thus, the antibodies and antigen binding fragments provided herein may also be referred to as AFP-L3 antibodies. Also provided are polynucleotides encoding the antibodies or antigen binding fragments of the invention, host cells expressing the antibodies and antigen binding fragments of the invention, methods for producing the antibodies and antigen binding fragments of the invention, and uses of the antibodies and antigen binding fragments of the invention. Also provided herein is a pretreatment agent facilitating the binding of the antibodies and antigen binding fragments of the invention to α-1,6-core-fucosylated AFP. The present invention further relates to kits comprising the antibodies and antigen binding fragments of the invention and optionally the pretreatment agent of the invention.
A monoclonal antibody or antigen binding fragment thereof specifically binding to α-1,6-core-fucosylated alpha-fetoprotein (AFP) or a partial sequence of AFP comprising said α-1,6-core-fucosylation, wherein the monoclonal antibody or antigen binding fragment comprises
(canceled)
A pretreatment reagent for treating a sample comprising α-1,6-core-fucosylated AFP, said pretreatment reagent comprising a reducing agent.
Dependencies are inferred from the claim text.